Dr. Siva Durairaj
@siva.d.clatr@sathyabama.ac.in
Assistant Professor (Research), Centre for Laboratory Animal Technology and Research, Sathyabama Institute of Science and Technology, Chennai, Tamil Nadu, India
Sathyabama Institute of Science and Technology, Chennai, Tamil Nadu, India
A Researcher with a profound expertise in the fields of Ecotoxicogenomics. Nanobiotechnology and Phytomedicine. The primary area of expertise lies in scrutinizing the molecular-level toxic impacts of Pharmaceutical and Personal Care Products (PPCPs) using in vivo animal experiments. Additionally, I have a distinct proficiency in assessing the medicinal properties of diverse herbal extracts and their bioactive constituents across a wide range of disease models such as anticancer, antidiabetic, reproductive toxicity, cardioprotective, hepatocurative, antiurolithiasis, obesity, antiarthritic, and wound healing studies.
EDUCATION
Ph.D.,
Environmental Biotechnology
Department of Environmental Biotechnology
Bharathidasan University
2013 to 2019
P.G Diploma
Environmental Genomics
Department of Environmental Biotechnology
Bharathidasan University
2011 to 2012
M. Phil.,
Environmental Biotechnology
Department of Environmental Biotechnology
Bharathidasan University
2010 to 2011
M. Sc.,
Eco-Biotechnology
Department of Environmental Biotechnology
Bharathidasan University
2008 to 2010
B. Sc.,
Biotechnology
Department of Biotechnology
Ponnaiyah Ramajayam College
Thanjavur – 614 904
2005 to 2008
RESEARCH, TEACHING, or OTHER INTERESTS
Biotechnology, Biomedical Engineering, Biomaterials, Pharmacology, Toxicology and Pharmaceutics
Scopus Publications
Scholar Citations
Scholar h-index
Scholar i10-index
Scopus Publications
Yumnam Asha Devi, Prathiba Gnanasekaran, Haorongbam Joldy Devi, Durairaj Siva, Srividya Seshadri, Malathy Balaraman Ravindrran, Subashini Partheeban, and Bhuvaneswari S.
Open Science Publishers LLP
This study aims to evaluate the antibiogram and antibacterial activity of Crassocephalum crepidioides leaf extract against the bacterial strains isolated from infected wounds. A total of 69 swab samples were obtained from various cases of infected wounds and 20 pure bacterial strains were isolated. The most prevalent organisms isolated from wound infections were Staphylococcus species and Escherichia coli (25%), followed by Klebsiella species (15%), Proteus species (10%), Providencia species (10%), Pseudomonas aeruginosa (5%), Acinetobacter baumannii (5%), and Enterobacter hormaechei (5%). The susceptibility pattern of all bacterial isolates was assessed against antibiotic discs using the Kirby Bauer Disc diffusion method. The results revealed that Gram-positive cocci exhibited 100 % susceptibility to Amikacin, Bacitracin, Oxytetracycline, and Vancomycin, however, showed 80% resistance to Novobiocin, Amoxicillin, Cephalothin, Erythromycin. Conversely, Gram-negative bacilli exhibited high resistance levels, including 86.7% to Ciprofloxacin, 80% to Carbericillin and Nitrofurantoin, 66.7% to Streptomycin and Tetracycline, 60% resistance to Co- Trimazine; however, they showed 73.3% sensitivity to Amikacin and 53.3% sensitivity to Kanamycin. Among the 20 bacterial strains, 13 (65%) were identified as multidrug-resistant (MDR) and 4 (20%) were extensively drug-resistant (XDR). In vitro antibacterial activity assay revealed that C. crepidioides leaf extract was found to be effective against all the Staphylococcus spp., E. hormaechei, A. baumannii, Providencia spp., two E. coli isolates and one Klebsiella spp. with the zone size ranging from 10.83 ± 0.28 to 25.83 ± 1.04, with minimum inhibitory concentration between 2.5 and 40 mg/ml, however, resistant to P. aeruginosa, Proteus spp., three E. coli isolates and two Klebsiella spp. Staphylococcus spp. was found to be the most inhibited wound isolates by C. crepidioides leaf extract. These findings suggest that C. crepidioides leaf extract has the potential to develop antibacterial agents against the MDR and XDR organisms causing wound infection, emphasizing the significant role of plant extracts in treating bacterial wound infections, thereby preventing the delay of the wound healing process.
Sudharsan Parthasarathy, Shaza H Aly, Siva Vijayakumar Tharumasivam, Durairaj Siva, Gobalan Krishnasamy, Ashajyothi Chavaan, and Mohamed El-Shazly
Oxford University Press (OUP)
Abstract Zebrafish (Danio rerio) has emerged as a valuable model organism in toxicology and drug discovery research. This article provides an overview of the significant contributions of zebrafish to advancing our understanding of toxicology and drug development. Zebrafish offers several advantages, including high fecundity, transparent embryos, and genetic tractability, making it an ideal system for studying drug toxicity and efficacy. The review article highlights key areas where zebrafish has made substantial contributions, such as assessing chemical toxicity, understanding drug metabolism and pharmacokinetics, and identifying novel therapeutic compounds. Furthermore, zebrafish-based assays and screening platforms have been developed to evaluate drug candidates and identify potential toxic effects and researchers have used zebrafish-based tests to study the therapeutic properties of natural compounds. The unique capabilities of zebrafish with its physiological and genetic similarities to humans, have propelled it to the forefront of toxicology and drug discovery, expanding the frontiers of research in these fields.
Haorongbam Joldy Devi, Prathiba Gnanasekaran, Arumugam Madan Kumar, Durairaj Siva, and Yumnam Asha Devi
Springer Science and Business Media LLC
Haorongbam Joldy Devi, Prathiba Gnanasekaran, Yumnam Asha Devi, Durairaj Siva, and Jaihitashee Jayashankar
Open Science Publishers LLP
Disinfectants are vital for infection prevention and environmental health maintenance. However, the use of chemical disinfectants has adverse effects on human health, including the development of antibiotic-resistance genes and resistance to disinfectants due to overuse and abuse. There is a critical need to find natural alternatives to reduce the problems caused by chemical disinfectants. The present study analyzed the antimicrobial activity of Syzygium cumini leaf extract (SCLE) against Staphylococcus aureus, Pseudomonas aeruginosa, Mucor sp., Candida albicans, and Aspergillus niger and its efficacy as a natural disinfectant was also evaluated, along with GC-MS analysis and in vitro toxicity test. The study showed that SCLE exhibited antimicrobial activity against all test organisms except A. niger. The minimum inhibitory concentration (MIC) against S. aureus, P. aeruginosa, Mucor sp., and C. albicans was 625, 1,250, 78, and 1,250 μg/ml, respectively. The minimum bactericidal concentration (MBC) against S. aureus and P. aeruginosa was 1,250 and 2,500 μg/ml, respectively. The minimum fungicidal concentration (MFC) against Mucor sp. and C. albicans was 156 and 5,000 μg/ml, respectively. SCLE demonstrated bactericidal and fungicidal properties based on MIC: MBC and MIC: MFC, with significant reductions in P. aeruginosa (99.99%), S. aureus (90.71%), Mucor sp. (92%), and C. albicans (73.45%) after the treatment. Syzygium cumini leaf extract, identified as nontoxic with an IC50 of 320μg/ml, proves promising as a potent natural disinfectant. This study marks the first report on the efficacy of S. cumini leaf extract against test organisms, showcasing its potential as a natural disinfecting agent against test organisms.
Kalaiselvi Seenivasan, Sankarganesh Arunachalam, Tirupathi Pichiah P. B., Sanjay B. Vasan, Meenakshi R. Venkateswaran, Durairaj Siva, Jeeva Gothandam, and Shanmugam Achiraman
Wiley
AbstractAdriamycin is an anticancer anthracycline drug that inhibits the progression of topoisomerase II activity and causes apoptosis. The effective clinical application of the drug is very much limited by its adverse drug reactions on various tissues. Most importantly, Adriamycin causes cardiomyopathy, one of the life‐threatening complications of the drug. Altered expression of PPARγ in adipocytes inhibited the glucose and fatty acids uptake by down regulating GLUT4 and CD36 expression and causes cardiotoxicity. Therefore, the influence of Adriamycin in cardiac ailments was investigated in vivo and in vitro. Adriamycin treated rats showed altered ECG profile, arrhythmic heartbeat with the elevated levels of CRP and LDH. Dysregulated lipid profiles with elevated levels of cholesterol and triglycerides were also observed. Possibilities of cardiac problems due to cardiomyopathy were analyzed through histopathology. Adriamycin treated rats showed no signs for atheromatous plaque formation in aorta but disorganized cardiomyocytes with myofibrillar loss and inflammation in heart tissue, indicative of cardiomyopathy. Reduced levels of antioxidant enzymes confirmed the incidence of oxidative stress. Adriamycin treatment significantly reduced glucose and insulin levels, creating energy demand due to decreased glucose and insulin levels with increased fatty acid accumulation, ultimately resulting in oxidative stress mediated cardiomyopathy. Since PPARs play a vital role in regulating oxidative stress, the effect of Adriamycin on PPARγ was analyzed by western blot. Adriamycin downregulated PPARγ in a dose‐dependent manner in H9C2 cells in vitro. Overall, our study suggests that Adriamycin alters glucose and lipid metabolism via PPARγ inhibition that leads to oxidative stress and cardiomyopathy that necessitates a different therapeutic approach.
C. Jayaseelan, D. Siva, C. Kamaraj, R. Thirugnanasambandam, V. Ganesh Kumar, B. Subashni, R. Ashokkumar, and D. Saravanan
Elsevier BV
Chidambaram Jayaseelan, Pooja Upadhyay, Dinkar Sahal, Chinnaperumal Kamaraj, Rajendran Thirugnanasambandam, Durairaj Siva, Durai Saravanan, and Rathinasamy Regina Mary
Elsevier BV
Durairaj Siva, Subramanian Abinaya, Durairaj Rajesh, Govindaraju Archunan, Parasuraman Padmanabhan, Balázs Gulyás, and Shanmugam Achiraman
MDPI AG
Doxorubicin is an extensively prescribed antineoplastic agent. It is also known for adverse effects, among which cardiotoxicity tops the list. The possible mechanism underlying doxorubicin (DOX)-mediated cardiotoxicity has been investigated in this study. Further, to reduce the DOX-mediated cardiotoxicity, DOX was conjugated with Chitosan Nanoparticles (DCNPs) and supplemented with propionic acid. Initially, the drug loading efficacy and conjugation of DOX with chitosan was confirmed by UV–Visible Spectroscopy (UV) and Fourier Transform Infrared Spectroscopy (FTIR). The average sizes of the synthesized Chitosan Nanoparticles (CNPs) and DCNPs were measured by Dynamic Light Scattering (DLS) analysis as 187.9 ± 1.05 nm and 277.3 ± 8.15 nm, respectively, and the zeta potential values were recorded as 55.2 ± 0.7 mV and 51.9 ± 1.0 mV, respectively. The size and shape of CNPs and DCNPs were recorded using a High-Resolution Electron Microscopy (HRTEM). The particles measured <30 nm and 33–84 nm, respectively. The toxic effects of DCNPs and propionic acid were evaluated in rat model. The data from the electrocardiogram (ECG), cardiac biomarkers, Peroxisome proliferator-activated receptor gamma (PPARγ) and histological observations indicated evidence of DOX-mediated cardiotoxicity, whereas the administration of DCNPs, as well as Propionic Acid (PA), brought about a restoration to normalcy and offered protection in the context of DOX-induced cardiotoxicity.
Durairaj Siva, Gunasekaran Srivethi, Poovanalingam Thirumalai Vasan, Durairaj Rajesh, Ahmed Alfarhan, and Rajakrishnan Rajagopal
Elsevier BV
Uma Maheshwari Rajadurai, Abirami Hariharan, Siva Durairaj, Fuad Ameen, Turki Dawoud, Suaad Alwakeel, Ilamathy Palanivel, Lakshmi Prabha Azhagiyamanavalan, and Joe Antony Jacob
Elsevier BV
Abbirami Elangovan, Siva Durairaj, Abinaya Subramanian, Sooraj Ramakrishnan, Dinesh Kumar Lakshmanan, Guna Ravichandran, and Sivasudha Thilagar
Springer Science and Business Media LLC
Hui Huang, Kuizhong Shan, Jingbing Liu, Xiaoxin Tao, Sivalingam Periyasamy, Siva Durairaj, Ziyu Jiang, and Joe Antony Jacob
Elsevier BV
Abbirami Elangovan, Abinaya Subramanian, Siva Durairaj, Jeyadevi Ramachandran, Dinesh Kumar Lakshmanan, Guna Ravichandran, Gayathri Nambirajan, and Sivasudha Thilagar
Elsevier BV
Padmanabhan RathnaKumari, Pachaan Kolanchinathan, Durairaj Siva, Bethunaickan Abirami, Vivekanandan Masilamani, George John, Shanmugam Achiraman, and Athmanathan Balasundaram
Elsevier BV
Durairaj Rajesh, Subramanian Muthukumar, Ganesan Saibaba, Durairaj Siva, Mohammad Abdulkader Akbarsha, Balázs Gulyás, Parasuraman Padmanabhan, and Govindaraju Archunan
Springer Science and Business Media LLC
AbstractTransportation of pheromones bound with carrier proteins belonging to lipocalin superfamily is known to prolong chemo-signal communication between individuals belonging to the same species. Members of lipocalin family (MLF) proteins have three structurally conserved motifs for delivery of hydrophobic molecules to the specific recognizer. However, computational analyses are critically required to validate and emphasize the sequence and structural annotation of MLF. This study focused to elucidate the evolution, structural documentation, stability and binding efficiency of estrus urinary lipocalin protein (EULP) with endogenous pheromones adopting in-silico and fluorescence study. The results revealed that: (i) EULP perhaps originated from fatty acid binding protein (FABP) revealed in evolutionary analysis; (ii) Dynamic simulation study shows that EULP is highly stable at below 0.45 Å of root mean square deviation (RMSD); (iii) Docking evaluation shows that EULP has higher binding energy with farnesol and 2-iso-butyl-3-methoxypyrazine (IBMP) than 2-naphthol; and (iv) Competitive binding and quenching assay revealed that purified EULP has good binding interaction with farnesol. Both, In-silico and experimental studies showed that EULP is an efficient binding partner to pheromones. The present study provides impetus to create a point mutation for increasing longevity of EULP to develop pheromone trap for rodent pest management.
Jacob Joe Antony, Murugaiyan Nivedheetha, Durairaj Siva, Ganesapandy Pradeepha, Palanivel Kokilavani, Seenivasan Kalaiselvi, Arunachalam Sankarganesh, Athmanathan Balasundaram, Vivekanandan Masilamani, and Shanmugam Achiraman
Elsevier BV
Jaganathan Sripriya, Sundaramurthy Anandhakumar, Shanmugam Achiraman, Jacob Joe Antony, Durairaj Siva, and Ashok M. Raichur
Elsevier BV
Jacob Joe Antony, Murugaiyan Nivedheetha, Durairaj Siva, Ganesapandy Pradeepha, Palanivel Kokilavani, Seenivasan Kalaiselvi, Arunachalam Sankarganesh, Athmanathan Balasundaram, Vivekanandan Masilamani, and Shanmugam Achiraman
Elsevier BV
Jacob Joe Antony, Mohamed Ali Ayisha Sithika, Thomas Amal Joseph, Udhayaraj Suriyakalaa, Arunachalam Sankarganesh, Durairaj Siva, Seenivasan Kalaiselvi, and Shanmugam Achiraman
Elsevier BV
Udhayaraj Suriyakalaa, Jacob Joe Antony, Subramanian Suganya, Durairaj Siva, Raman Sukirtha, Soundarrajan Kamalakkannan, P.B. Tirupathi Pichiah, and Shanmugam Achiraman
Elsevier BV
Periyasamy Sivalingam, Jacob Joe Antony, Durairaj Siva, Shanmugam Achiraman, and Kumarasamy Anbarasu
Elsevier BV
Jacob Joe Antony, Periyasamy Sivalingam, Durairaj Siva, Soundararajan Kamalakkannan, Kumarasamy Anbarasu, Raman Sukirtha, Muthukalingan Krishnan, and Shanmugam Achiraman
Elsevier BV